Search research articles
Contact Us
Filters
Showing results (181-190 of 276) with videos related to
Page
of 28
Sort By:
American Journal of Hematology
|
September 6, 2023
Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel
Farhad Ravandi, Jacqueline Cloos, Francesco Buccisano, et al.
Haematologica
|
October 13, 2022
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia
Keith W Pratz, Jason Kaplan, Moshe Levy, et al.
The Lancet. Haematology
|
March 29, 2023
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study
Guillermo Garcia-Manero, Aaron D Goldberg, Eric S Winer, et al.
Leukemia
|
October 3, 2023
Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients
Ekaterina Jahn, Maral Saadati, Pierre Fenaux, et al.
Leukemia
|
August 17, 2023
Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients
Ekaterina Jahn, Maral Saadati, Pierre Fenaux, et al.
Leukemia & Lymphoma
|
August 12, 2023
Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with <i>RARA</i> gene overexpression
Eytan M Stein, Stephane de Botton, Thomas Cluzeau, et al.
Journal of Hematology & Oncology
|
February 25, 2021
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial
Robert J Kreitman, Claire Dearden, Pier Luigi Zinzani, et al.
Journal of Hematology & Oncology
|
January 17, 2025
Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial
Jorge E Cortes, Gail J Roboz, Maria R Baer, et al.
Cancer
|
November 21, 2014
Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium
Elias J Jabbour, Guillermo Garcia-Manero, Paolo Strati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2009
Pomalidomide is active in the treatment of anemia associated with myelofibrosis
Ayalew Tefferi, Srdan Verstovsek, Giovanni Barosi, et al.
Page
of 28
Search research articles
Search
Showing results (181-190 of 276) with videos related to
Sort By:
Page
of 28
American Journal of Hematology
|
September 6, 2023
Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel
Farhad Ravandi, Jacqueline Cloos, Francesco Buccisano, et al.
Haematologica
|
October 13, 2022
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia
Keith W Pratz, Jason Kaplan, Moshe Levy, et al.
The Lancet. Haematology
|
March 29, 2023
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study
Guillermo Garcia-Manero, Aaron D Goldberg, Eric S Winer, et al.
Leukemia
|
October 3, 2023
Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients
Ekaterina Jahn, Maral Saadati, Pierre Fenaux, et al.
Leukemia
|
August 17, 2023
Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients
Ekaterina Jahn, Maral Saadati, Pierre Fenaux, et al.
Leukemia & Lymphoma
|
August 12, 2023
Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with <i>RARA</i> gene overexpression
Eytan M Stein, Stephane de Botton, Thomas Cluzeau, et al.
Journal of Hematology & Oncology
|
February 25, 2021
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial
Robert J Kreitman, Claire Dearden, Pier Luigi Zinzani, et al.
Journal of Hematology & Oncology
|
January 17, 2025
Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial
Jorge E Cortes, Gail J Roboz, Maria R Baer, et al.
Cancer
|
November 21, 2014
Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium
Elias J Jabbour, Guillermo Garcia-Manero, Paolo Strati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2009
Pomalidomide is active in the treatment of anemia associated with myelofibrosis
Ayalew Tefferi, Srdan Verstovsek, Giovanni Barosi, et al.
Page
of 28